(Q35917148)

11 August 2017

1 reference

title

The next generation of HIV/AIDS drugs: novel and developmental antiHIV drugs and targets (English)

1 reference

11 August 2017

1 reference

Jim A Turpin

1

1 reference

11 August 2017

publication date

1 June 2003

1 reference

Expert Review of Anti-infective Therapy

11 August 2017

published in

1 reference

11 August 2017

volume

1

1 reference

11 August 2017

issue

1

1 reference

11 August 2017

page(s)

97-128

1 reference

Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group.

11 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

A review of vaccines for HIV prevention.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

HIV-1 Tat-based vaccines: from basic science to clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Considerations and development of topical microbicides to inhibit the sexual transmission of HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Alterations in the immune response of human immunodeficiency virus (HIV)-infected subjects treated with an HIV-specific protease inhibitor, ritonavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Human immunodeficiency virus type 1 in the semen of men receiving highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Randomized study of saquinavir with ritonavir or nelfinavir together with delavirdine, adefovir, or both in human immunodeficiency virus-infected adults with virologic failure on indinavir: AIDS Clinical Trials Group Study 359.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

21 January 2018

Immune reconstitution

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

A stable latent reservoir for HIV-1 in resting CD4(+) T lymphocytes in infected children

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Long-term survival and virus production in human primary macrophages infected by human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Macrophages and HIV infection: therapeutical approaches toward this strategic virus reservoir

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

HIV-1 drug resistance profiles in children and adults with viral load of <50 copies/ml receiving combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Persistence of wild-type virus and lack of temporal structure in the latent reservoir for human immunodeficiency virus type 1 in pediatric patients with extensive antiretroviral exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Constant mean viral copy number per infected cell in tissues regardless of high, low, or undetectable plasma HIV RNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Incidence and impact of resistance against approved antiretroviral drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Lipodystrophy syndrome by HAART in HIV-infected patients: manifestation, mechanisms and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Hypoadiponectinemia is associated with insulin resistance, hypertriglyceridemia, and fat redistribution in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Charting HIV's remarkable voyage through the cell: Basic science as a passport to future therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

The plasma membrane as a combat zone in the HIV battlefield

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Strategies in the design of antiviral drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Current status of antiretroviral therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Transmission fitness of drug-resistant human immunodeficiency virus and the prevalence of resistance in the antiretroviral-treated population

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Antiretroviral pharmacokinetics in the paediatric population: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

L-743, 726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Structural basis for the resilience of efavirenz (DMP-266) to drug resistance mutations in HIV-1 reverse transcriptase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Cross-resistance among nonnucleoside reverse transcriptase inhibitors limits recycling efavirenz after nevirapine failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Highlights in the development of new antiviral agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Novel compounds in preclinical/early clinical development for the treatment of HIV infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Current lead natural products for the chemotherapy of human immunodeficiency virus (HIV) infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Gene therapy for human immunodeficiency virus infection: genetic antiviral strategies and targets for intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

HIV-1 Entry Cofactor: Functional cDNA Cloning of a Seven-Transmembrane, G Protein-Coupled Receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

New therapeutics that modulate chemokine networks

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Inhibitors of protein-disulfide isomerase prevent cleavage of disulfide bonds in receptor-bound glycoprotein 120 and prevent HIV-1 entry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Cell-surface heparan sulfate proteoglycan mediates HIV-1 infection of T-cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Beyond receptor expression: the influence of receptor conformation, density, and affinity in HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Inhibitory effect of dextran sulfate and heparin on the replication of human immunodeficiency virus (HIV) in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Mechanism of inhibitory effect of dextran sulfate and heparin on replication of human immunodeficiency virus in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Inhibition of human immunodeficiency virus replication by the sulfonated stilbene dye resobene

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

The bis-azo compound FP-21399 inhibits HIV-1 replication by preventing viral entry

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

A fusion inhibitor (FP-21399) for the treatment of human immunodeficiency virus infection: a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Cyanovirin-N, a potent human immunodeficiency virus-inactivating protein, blocks both CD4-dependent and CD4-independent binding of soluble gp120 (sgp120) to target cells, inhibits sCD4-induced binding of sgp120 to cell-associated CXCR4, and dissocia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Inhibition of the human immunodeficiency virus type 1 integrase by guanosine quartet structures

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Cell turnover and cell tropism in HIV-1 infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Multiple extracellular elements of CCR5 and HIV-1 entry: dissociation from response to chemokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Aminooxypentane-RANTES induces CCR5 internalization but inhibits recycling: a novel inhibitory mechanism of HIV infectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Anti-human immunodeficiency virus activity of a novel synthetic peptide, T22 ([Tyr-5,12, Lys-7]polyphemusin II): a possible inhibitor of virus-cell fusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

A low-molecular-weight inhibitor against the chemokine receptor CXCR4: a strong anti-HIV peptide T140.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

A small-molecule inhibitor directed against the chemokine receptor CXCR4 prevents its use as an HIV-1 coreceptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Safe use of the CXCR4 inhibitor ALX40-4C in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Discovery of novel, potent, and selective small-molecule CCR5 antagonists as anti-HIV-1 agents: synthesis and biological evaluation of anilide derivatives with a quaternary ammonium moiety

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Piperazine-based CCR5 antagonists as HIV-1 inhibitors. II. Discovery of 1-[(2,4-dimethyl-3-pyridinyl)carbonyl]-4- methyl-4-[3(S)-methyl-4-[1(S)-[4-(trifluoromethyl)phenyl]ethyl]-1-piperazinyl]- piperidine N1-oxide (Sch-350634), an orally bioavailabl

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Novel sulfonated and phosphonated analogs of distamycin which inhibit the replication of HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Naturally occurring CCR5 extracellular and transmembrane domain variants affect HIV-1 Co-receptor and ligand binding function

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 3: a proposed pharmacophore model for 1-[N-(methyl)-N-(phenylsulfonyl)amino]-2-(phenyl)-4-[4-(substituted)piperidin-1-yl]butanes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

CCR5 antagonists: bicyclic isoxazolidines as conformationally constrained N-1-substituted pyrrolidines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists. Part 2: lead optimization affording selective, orally bioavailable compounds with potent anti-HIV activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Design, synthesis, and SAR of heterocycle-containing antagonists of the human CCR5 receptor for the treatment of HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

HIV-1 entry inhibitors in the side pocket

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Sensitivity to a nonpeptidic compound (RPR103611) blocking human immunodeficiency virus type 1 Env-mediated fusion depends on sequence and accessibility of the gp41 loop region

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Structure-based identification of small molecule antiviral compounds targeted to the gp41 core structure of the human immunodeficiency virus type 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Selection of gp41-mediated HIV-1 cell entry inhibitors from biased combinatorial libraries of non-natural binding elements

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: a platform for antiviral drug design

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Chicoric acid analogues as HIV-1 integrase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Diketo acid inhibitor mechanism and HIV-1 integrase: implications for metal binding in the active site of phosphotransferase enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

HIV-1 integrase inhibitors that compete with the target DNA substrate define a unique strand transfer conformation for integrase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Structural determinants for HIV-1 integrase inhibition by beta-diketo acids

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

The nucleocapsid protein isolated from HIV-1 particles binds zinc and forms retroviral-type zinc fingers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Structural biology of HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Amino acid sequence homology in gag region of reverse transcribing elements and the coat protein gene of cauliflower mosaic virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Strict conservation of the retroviral nucleocapsid protein zinc finger is strongly influenced by its role in viral infection processes: characterization of HIV-1 particles containing mutant nucleocapsid zinc-coordinating sequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Structure of the HIV-1 nucleocapsid protein bound to the SL3 psi-RNA recognition element

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Interactions between HIV-1 nucleocapsid protein and viral DNA may have important functions in the viral life cycle

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Influence of human immunodeficiency virus nucleocapsid protein on synthesis and strand transfer by the reverse transcriptase in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Zinc finger structures in the human immunodeficiency virus type 1 nucleocapsid protein facilitate efficient minus- and plus-strand transfer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Human immunodeficiency virus type 1 nucleocapsid zn(2+) fingers are required for efficient reverse transcription, initial integration processes, and protection of newly synthesized viral DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Enhancement of the basal-level activity of HIV-1 long terminal repeat by HIV-1 nucleocapsid protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Human immunodeficiency virus type 1 nucleocapsid protein nuclear localization mediates early viral mRNA expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

The site of antiviral action of 3-nitrosobenzamide on the infectivity process of human immunodeficiency virus in human lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Inhibition of HIV-1 infectivity by zinc-ejecting aromatic C-nitroso compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Inhibitors of HIV nucleocapsid protein zinc fingers as candidates for the treatment of AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

A new class of anti-HIV-1 agents targeted toward the nucleocapsid protein NCp7: the 2,2'-dithiobisbenzamides

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Reactivity of the HIV-1 nucleocapsid protein p7 zinc finger domains from the perspective of density-functional theory

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Anti-HIV agents that selectively target retroviral nucleocapsid protein zinc fingers without affecting cellular zinc finger proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Evaluation of selected chemotypes in coupled cellular and molecular target-based screens identifies novel HIV-1 zinc finger inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Inhibition of the early phase of HIV replication by an isothiazolone, PD 161374.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Synthesis and biological properties of novel pyridinioalkanoyl thiolesters (PATE) as anti-HIV-1 agents that target the viral nucleocapsid protein zinc fingers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Synthesis and biological properties of amino acid amide ligand-based pyridinioalkanoyl thioesters as anti-HIV agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Benzamide-based thiolcarbamates: a new class of HIV-1 NCp7 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

ADA, a potential anti-HIV drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Azodicarbonamide inhibits HIV-1 replication by targeting the nucleocapsid protein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Ribonucleotide reductase and thymidine phosphorylation: two potential targets of azodicarbonamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Delavirdine: a review of its use in HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

SJ-3366, a unique and highly potent nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 (HIV-1) that also inhibits HIV-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

The biological effects of structural variation at the meta position of the aromatic rings and at the end of the alkenyl chain in the alkenyldiarylmethane series of non-nucleoside reverse transcriptase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

The ribonuclease H activity of HIV-1 reverse transcriptase: further biochemical characterization and search of inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Nevirapine alters the cleavage specificity of ribonuclease H of human immunodeficiency virus 1 reverse transcriptase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Mutants of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase resistant to nonnucleoside reverse transcriptase inhibitors demonstrate altered rates of RNase H cleavage that correlate with HIV-1 replication fitness in cell culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Mutational analysis of Tyr-501 of HIV-1 reverse transcriptase. Effects on ribonuclease H activity and inhibition of this activity by N-acylhydrazones

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Susceptibility to PNU-140690 (Tipranavir) of human immunodeficiency virus type 1 isolates derived from patients with multidrug resistance to other protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Design and selection of DMP 850 and DMP 851: the next generation of cyclic urea HIV protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

HIV-1 regulatory proteins: targets for novel drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Selective CXCR4 antagonism by Tat: implications for in vivo expansion of coreceptor use by HIV-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

An inhibitor of the Tat/TAR RNA interaction that effectively suppresses HIV-1 replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Neomycin B-arginine conjugate, a novel HIV-1 Tat antagonist: synthesis and anti-HIV activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Long-term culture of HIV-1-infected cells with the transcription inhibitor K-37.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

21 January 2018

THE HIV-1 REV PROTEIN

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Inhibition of HIV replication by dominant negative mutants of Sam68, a functional homolog of HIV-1 Rev.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Leptomycin B is an inhibitor of nuclear export: inhibition of nucleo-cytoplasmic translocation of the human immunodeficiency virus type 1 (HIV-1) Rev protein and Rev-dependent mRNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Leptomycin B inhibition of signal-mediated nuclear export by direct binding to CRM1

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Leptomycin B inactivates CRM1/exportin 1 by covalent modification at a cysteine residue in the central conserved region

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

A synthetic HIV-1 Rev inhibitor interfering with the CRM1-mediated nuclear export

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Small molecule modulators of HIV Rev/Rev response element interaction identified by random screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

A Novel Solid-Phase Assembly for Identifying Potent and Selective RNA Ligands We thank Professors David Wilson and David Boykin for a generous gift of the aromatic amidine derivatives and Professor Kol for a generous gift of eilatin-containing compl

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Formation of a human immunodeficiency virus type 1 core of optimal stability is crucial for viral replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Antiviral agents targeted to interact with viral capsid proteins and a possible application to human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Antiviral inhibition of the HIV-1 capsid protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

trans-Complementation rescue of cyclophilin A-deficient viruses reveals that the requirement for cyclophilin A in human immunodeficiency virus type 1 replication is independent of its isomerase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Human immunodeficiency virus type 1 uses lipid raft-colocalized CD4 and chemokine receptors for productive entry into CD4(+) T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Evidence for budding of human immunodeficiency virus type 1 selectively from glycolipid-enriched membrane lipid rafts

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Role for human immunodeficiency virus type 1 membrane cholesterol in viral internalization

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Toxicity and therapeutic effects in mice of liposome-encapsulated nystatin for systemic fungal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Evaluation and management of dyslipidemia in patients with HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Visualization of the intracellular behavior of HIV in living cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Association of integrase, matrix, and reverse transcriptase antigens of human immunodeficiency virus type 1 with viral nucleic acids following acute infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Dynamic disruptions in nuclear envelope architecture and integrity induced by HIV-1 Vpr.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

A nuclear localization signal within HIV-1 matrix protein that governs infection of non-dividing cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

HIV-1 infection of nondividing cells through the recognition of integrase by the importin/karyopherin pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Cytoplasmic recruitment of INI1 and PML on incoming HIV preintegration complexes: interference with early steps of viral replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Retrocyclin: a primate peptide that protects cells from infection by T- and M-tropic strains of HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Interactions between HIV1 Nef and vacuolar ATPase facilitate the internalization of CD4

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Flavopiridol: the first cyclin-dependent kinase inhibitor in human clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Preclinical and clinical development of cyclin-dependent kinase modulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Flavopiridol inhibits P-TEFb and blocks HIV-1 replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

P-TEFb kinase is required for HIV Tat transcriptional activation in vivo and in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Organization of immature human immunodeficiency virus type 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Identification of a host protein essential for assembly of immature HIV-1 capsids

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Role of capsid precursor processing and myristoylation in morphogenesis and infectivity of human immunodeficiency virus type 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Role of the C terminus Gag protein in human immunodeficiency virus type 1 virion assembly and maturation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Ubiquitin is part of the retrovirus budding machinery

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Proteasome inhibition interferes with gag polyprotein processing, release, and maturation of HIV-1 and HIV-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

A role for ubiquitin ligase recruitment in retrovirus release

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Effect of nucleoside analogs and non-nucleoside inhibitors of HIV-1 reverse transcriptase on cell-free virions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.97

21 January 2018

Identifiers

DOI

10.1586/14787210.1.1.97

1 reference

11 August 2017

1 reference